Citigroup downgraded Bausch + Lomb from Buy to Neutral and set a new price target of $22.00 from $24.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/1/2025 | $16.00 | Neutral | Goldman |
| 5/2/2025 | $20.00 → $15.00 | Buy | H.C. Wainwright |
| 3/28/2025 | $24.00 → $15.00 | Overweight → Equal Weight | Wells Fargo |
| 12/11/2024 | $24.00 → $22.00 | Buy → Neutral | Citigroup |
| 12/2/2024 | $19.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/15/2024 | $19.00 → $25.00 | In-line → Outperform | Evercore ISI |
| 7/10/2024 | $19.00 | Outperform | Raymond James |
| 5/6/2024 | $16.00 → $18.00 | Equal-Weight → Overweight | Morgan Stanley |
Goldman initiated coverage of Bausch + Lomb with a rating of Neutral and set a new price target of $16.00
H.C. Wainwright reiterated coverage of Bausch + Lomb with a rating of Buy and set a new price target of $15.00 from $20.00 previously
Wells Fargo downgraded Bausch + Lomb from Overweight to Equal Weight and set a new price target of $15.00 from $24.00 previously
8-K - Bausch & Lomb Corp (0001860742) (Filer)
10-Q - Bausch & Lomb Corp (0001860742) (Filer)
8-K - Bausch & Lomb Corp (0001860742) (Filer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Executive Vice President and Chief Financial Officer Sam Eldessouky will participate in a fireside chat at the 2025 Citi Global Healthcare Conference on Wednesday, Dec. 3, 2025, at 9:00 a.m. ET. A live webcast, as well as a post-event recording, will be available on the Investor Relations page of the Bausch + Lomb website: http://ir.bausch.com/investors/events-presentations. About Bausch + Lomb Our mission is simple – we help people see better to live better, all over the world. For nearly two centu
NEW YORK, Nov. 13, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on November 13th Stocks are little changed Thursday morning after two major developments: A new partnership between NYSE-listed TKO Group Holdings and Polymarket, and the end of the longest U.S. Government shutdown.TKO Group Holdings and Polymarket will ring the opening bell with several guests including TKO Chair and CEO Ari Emanuel, Polymarket CEO Shayne Coplan, UFC CEO Dana White, and
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will outline the next chapter of its evolution today during an investor day event at the New York Stock Exchange. Leading Through Reinvention Over the past few years, Bausch + Lomb has undergone a complete transformation by redefining how it operates. The company has sharpened its focus through simplification, rebuilt its culture around accountability and innovation and embraced AI and other new technologies to succeed now and well into the future. "Bausch + Lomb today is a fundamentally different company than it was just a few years ago," said Brent Sa
Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For Against Broker Non-Votes Nathalie Bernier 337,617,248 1,924,336 8,383,437 Gary Hu 337,591,706 1,949,878 8,383,437 Brett Icahn 337,474,287 2,067,297 8,383,437 Sarah B. Kavanagh 337,602,211 1,939,373
Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai
SC 13G - Bausch & Lomb Corp (0001860742) (Subject)
Revenue of $1.281 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $28 Million Adjusted EBITDA (non-GAAP)1 of $243 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $243 Million Revenue Grew 7% as Reported and 6% on a Constant Currency1 Basis Compared to the Third Quarter of 2024 Updating Full-Year 2025 Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2025 financial results. "We're delivering on the vision we laid out in 2023, with a base business engine that con
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 29, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Bausch + Lomb will hold an investor day on Thursday, Nov. 13, 2025, where the company will provide a business update and highlight its product pipeline which features potential game-changing innovations in each business unit. T
Revenue of $1.278 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $62 Million Adjusted EBITDA (non-GAAP)1 of $191 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $192 Million Revenue Grew 5% as Reported and 3% on a Constant Currency1 Basis Compared to the Second Quarter of 2024, which Absorbs the enVista® Intraocular Lenses Voluntary Recall Raising Full-Year 2025 Guidance to Reflect Solid Business Performance and Impact of Foreign Exchange Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2025 financial results. "Our con
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)